Purpose The optimal immune globulin replacement dosages required over time to minimize infection risks in patients with Primary Antibody Deficiencies are not definitely established. As with many interventions, there may be specific subgroups of patients who are more likely to benefit from treatment with higher or lower dosages. The aim of the study was to verify the efficacy of a rationale for individualized immune globulin utilization and to elucidate the effects of care on patient outcome. Methods Single centre interventional study on 108 patients with Primary Antibody Deficiencies. The objective was to determine for each patient the best interval between immune globulins administration in order to: • Keep IgG trough levels >500 mg/dL, • ...
Exogenous antibody therapy to protect patients against infections and toxins is over 100 years old, ...
Immunoglobulin therapy is the administration of human polyvalent IgG and represents the most effecti...
A highly concentrated (20%) immunoglobulin (Ig)G preparation for subcutaneous administration (IGSC 2...
The optimal immune globulin replacement dosages required over time to minimize infection risks in pa...
The consumption of immunoglobulins (Ig) is increasing due to better recognition of antibody deficien...
The consumption of immunoglobulins (Ig) is increasing due to better recognition of antibody deficien...
The consumption of immunoglobulins (Ig) is increasing due to better recognition of antibody deficien...
A 5-years multicenter prospective study on 201 patients with common variable immunodeficiencies and ...
A 5-years multicenter prospective study on 201 patients with common variable immunodeficiencies and ...
Primary antibody deficiencies (PAD) constitute the majority of all primary immunodeficiency diseases...
A 5-years multicenter prospective study on 201 patients with common variable immunodeficiencies and ...
Exogenous antibody therapy to protect patients against infections and toxins is over 100 years old, ...
Immunoglobulin therapy is the administration of human polyvalent IgG and represents the most effecti...
A highly concentrated (20%) immunoglobulin (Ig)G preparation for subcutaneous administration (IGSC 2...
The optimal immune globulin replacement dosages required over time to minimize infection risks in pa...
The consumption of immunoglobulins (Ig) is increasing due to better recognition of antibody deficien...
The consumption of immunoglobulins (Ig) is increasing due to better recognition of antibody deficien...
The consumption of immunoglobulins (Ig) is increasing due to better recognition of antibody deficien...
A 5-years multicenter prospective study on 201 patients with common variable immunodeficiencies and ...
A 5-years multicenter prospective study on 201 patients with common variable immunodeficiencies and ...
Primary antibody deficiencies (PAD) constitute the majority of all primary immunodeficiency diseases...
A 5-years multicenter prospective study on 201 patients with common variable immunodeficiencies and ...
Exogenous antibody therapy to protect patients against infections and toxins is over 100 years old, ...
Immunoglobulin therapy is the administration of human polyvalent IgG and represents the most effecti...
A highly concentrated (20%) immunoglobulin (Ig)G preparation for subcutaneous administration (IGSC 2...